Intravenous thrombolysis in acute ischemic stroke: standard and potential future applications

References

• Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med 1995;333(24):1581-7
   PubMed Web of Science ®Google Scholar
• Hacke W, Kaste M, Fieschi C, et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS). JAMA 1995;274(13):1017-25
   PubMed Web of Science ®Google Scholar
• Hacke W, Kaste M, Fieschi C, et al. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators. Lancet 1998;352(9136):1245-51
   PubMed Web of Science ®Google Scholar
• Wardlaw JM, Zoppo G, Yamaguchi T, Berge E. Thrombolysis for acute ischaemic stroke. Cochrane Database Syst Rev 2003(3):CD000213
   PubMed Web of Science ®Google Scholar
• Wardlaw JM, Sandercock PA, Berge E. Thrombolytic therapy with recombinant tissue plasminogen activator for acute ischemic stroke: where do we go from here? A cumulative meta-analysis. Stroke 2003;34(6):1437-42
   PubMed Web of Science ®Google Scholar
• Hacke W, Donnan G, Fieschi C, et al. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet 2004;363(9411):768-74
   PubMed Web of Science ®Google Scholar
• Hacke W, Kaste M, Bluhmki E, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med 2008;359(13):1317-29
   PubMed Web of Science ®Google Scholar
• Lees KR, Bluhmki E, von Kummer R, et al. Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet 2010;375(9727):1695-703
   PubMed Web of Science ®Google Scholar
• Meretoja A, Putaala J, Tatlisumak T, et al. Off-label thrombolysis is not associated with poor outcome in patients with stroke. Stroke 2010;41(7):1450-8
   PubMedGoogle Scholar
• Sandercock P, Wardlaw JM, Lindley RI, et al. The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial. Lancet 2012;379(9834):2352-63
   PubMed Web of Science ®Google Scholar
• Lyden PD. In anticipation of International Stroke Trial-3 (IST-3). Stroke 2012;43(6):1691-4
   PubMedGoogle Scholar
• Sandercock P, Lindley R, Wardlaw J, et al. Statistical analysis plan for the third International Stroke Trial (IST-3); part of a ‘thread’ of reports of the trial. Int J Stroke 2012;7(3):186-7
   PubMedGoogle Scholar
• Wardlaw JM, Murray V, Berge E, et al. Recombinant tissue plasminogen activator for acute ischaemic stroke: an updated systematic review and meta-analysis. Lancet 2012;379(9834):2364-72
   PubMed Web of Science ®Google Scholar
• Davis SM, Donnan GA, Parsons MW, et al. Effects of alteplase beyond 3 h after stroke in the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET): a placebo-controlled randomised trial. Lancet Neurol 2008;7(4):299-309
   PubMed Web of Science ®Google Scholar
• Emberson J, Hacke W. Impact of treatment delay, age and stroke severity on the effects of intravenous thrombolysis with alteplase in acute ischemic stroke: an individual-patient-data meta-analysis (abstract LB2). Presented at International Stroke Conference; San Diego, CA, USA; 2014
   Google Scholar
• Slot KB, Berge E, Dorman P, et al. Impact of functional status at six months on long term survival in patients with ischaemic stroke: prospective cohort studies. BMJ 2008;336(7640):376-9
   PubMed Web of Science ®Google Scholar
• Mishra NK, Ahmed N, Andersen G, et al. Thrombolysis in very elderly people: controlled comparison of SITS International Stroke Thrombolysis Registry and Virtual International Stroke Trials Archive. BMJ 2010;341:c6046
   PubMedGoogle Scholar
• Bhatnagar P, Sinha D, Parker RA, et al. Intravenous thrombolysis in acute ischaemic stroke: a systematic review and meta-analysis to aid decision making in patients over 80 years of age. J Neurol Neurosurg Psychiatry 2011;82(7):712-17
   PubMedGoogle Scholar
• Fonarow G, Zhao X, Smith E, et al. Improving door-to-needle times in acute ischemic stroke: principal results from the target: stroke initiative (abstract LB12). Presented at International Stroke Conference; San Diego, CA, USA; 2014
   Google Scholar
• Arboix A, Miguel M, Císcar E, et al. Cardiovascular risk factors in patients aged 85 or older with ischemic stroke. Clin Neurol Neurosurg 2006;108(7):638-43
   PubMed Web of Science ®Google Scholar
• Pendlebury ST, Rothwell PM. Prevalence, incidence, and factors associated with pre-stroke and post-stroke dementia: a systematic review and meta-analysis. Lancet Neurol 2009;8(11):1006-18
   PubMed Web of Science ®Google Scholar
• Leys D, Hénon H, Mackowiak-Cordoliani MA, Pasquier F. Poststroke dementia. Lancet Neurol 2005;4(11):752-9
   PubMed Web of Science ®Google Scholar
• Alshekhlee A, Li CC, Chuang SY, et al. Does dementia increase risk of thrombolysis?: a case-control study. Neurology 2011;76(18):1575-80
   PubMedGoogle Scholar
• Busl KM, Nogueira RG, Yoo AJ, et al. Prestroke dementia is associated with poor outcomes after reperfusion therapy among elderly stroke patients. J Stroke Cerebrovasc Dis 2013;22(6):718-24
   PubMedGoogle Scholar
• Cordonnier C, van der Flier WM, Sluimer JD, et al. Prevalence and severity of microbleeds in a memory clinic setting. Neurology 2006;66(9):1356-60
   PubMed Web of Science ®Google Scholar
• Neumann-Haefelin T, Hoelig S, Berkefeld J, et al. Leukoaraiosis is a risk factor for symptomatic intracerebral hemorrhage after thrombolysis for acute stroke. Stroke 2006;37(10):2463-6
   PubMedGoogle Scholar
• Fiehler J, Albers GW, Boulanger JM, et al. Bleeding risk analysis in stroke imaging before thromboLysis (BRASIL): pooled analysis of T2*-weighted magnetic resonance imaging data from 570 patients. Stroke 2007;38(10):2738-44
   PubMed Web of Science ®Google Scholar
• Roussel BD, Macrez R, Jullienne A, et al. Age and albumin D site-binding protein control tissue plasminogen activator levels: neurotoxic impact. Brain 2009;132(Pt 8):2219-30
   PubMedGoogle Scholar
• Iadecola C. Neurovascular regulation in the normal brain and in Alzheimer’s disease. Nat Rev Neurosci 2004;5(5):347-60
   PubMed Web of Science ®Google Scholar
• Teter B, Ashford JW. Neuroplasticity in Alzheimer’s disease. J Neurosci Res 2002;70(3):402-37
   PubMedGoogle Scholar
• Leys D, Cordonnier C. rt-PA for ischaemic stroke: what will the next question be? Lancet 2012;379(9834):2320-1
   PubMedGoogle Scholar
• Levine SR, Khatri P, Broderick JP, et al. Review, historical context, and clarifications of the NINDS rt-PA stroke trials exclusion criteria: part 1: rapidly improving stroke symptoms. Stroke 2013;44(9):2500-5
   PubMedGoogle Scholar
• Tsivgoulis G, Sharma VK, Mikulik R, et al. Intravenous thrombolysis for acute ischemic stroke occurring during hospitalization for transient ischemic attack. Int J Stroke 2014;9:413-18
   PubMed Web of Science ®Google Scholar
• Smith EE, Fonarow GC, Reeves MJ, et al. Outcomes in mild or rapidly improving stroke not treated with intravenous recombinant tissue-type plasminogen activator: findings from Get With The Guidelines-Stroke. Stroke 2011;42(11):3110-15
   PubMed Web of Science ®Google Scholar
• Barber PA, Zhang J, Demchuk AM, et al. Why are stroke patients excluded from TPA therapy? An analysis of patient eligibility. Neurology 2001;56(8):1015-20
   PubMed Web of Science ®Google Scholar
• Smith EE, Abdullah AR, Petkovska I, et al. Poor outcomes in patients who do not receive intravenous tissue plasminogen activator because of mild or improving ischemic stroke. Stroke 2005;36(11):2497-9
   PubMedGoogle Scholar
• Hills NK, Johnston SC. Why are eligible thrombolysis candidates left untreated? Am J Prev Med 2006;31(6 Suppl 2):S210-16
   PubMed Web of Science ®Google Scholar
• Balucani C, Levine SR. Mild stroke and rapidly improving symptoms: it’s not always a happy ending. Stroke 2011;42(11):3005-7
   PubMedGoogle Scholar
• Nedeltchev K, Schwegler B, Haefeli T, et al. Outcome of stroke with mild or rapidly improving symptoms. Stroke 2007;38(9):2531-5
   PubMedGoogle Scholar
• Engelter ST, Gostynski M, Papa S, et al. Barriers to stroke thrombolysis in a geographically defined population. Cerebrovasc Dis 2007;23(2-3):211-15
   PubMedGoogle Scholar
• George MG, Tong X, McGruder H, et al. Paul Coverdell National Acute Stroke Registry Surveillance - four states, 2005-2007. MMWR Surveill Summ 2009;58(7(1):23
   Google Scholar
• Arboix A, García-Eroles L, Comes E, et al. Predicting spontaneous early neurological recovery after acute ischemic stroke. Eur J Neurol 2003;10(4):429-35
   PubMedGoogle Scholar
• Arboix A, Blanco-Rojas L, Martí-Vilalta JL. Advancements in understanding the mechanisms of symptomatic lacunar ischemic stroke: translation of knowledge to prevention strategies. Expert Rev Neurother 2014;14:261-76
   PubMed Web of Science ®Google Scholar
• Griebe M, Fischer E, Kablau M, et al. Thrombolysis in patients with lacunar stroke is safe: an observational study. J Neurol 2014;261:405-11
   PubMedGoogle Scholar
• Adeoye O, Hornung R, Khatri P, Kleindorfer D. Recombinant tissue-type plasminogen activator use for ischemic stroke in the United States: a doubling of treatment rates over the course of 5 years. Stroke 2011;42(7):1952-5
   PubMed Web of Science ®Google Scholar
• Kleindorfer D, Lindsell CJ, Brass L, et al. National US estimates of recombinant tissue plasminogen activator use: ICD-9 codes substantially underestimate. Stroke 2008;39(3):924-8
   PubMed Web of Science ®Google Scholar
• Kaste M. Stroke: advances in thrombolysis. Lancet Neurol 2013;12(1):2-4
   PubMedGoogle Scholar
• Kleindorfer D, de los Rios La Rosa F, Khatri P, et al. Temporal trends in acute stroke management. Stroke 2013;44(6 Suppl 1):S129-31
   Google Scholar
• de Los Ríos la Rosa F, Khoury J, Kissela BM, et al. Eligibility for intravenous recombinant tissue-type plasminogen activator within a population: the effect of the European Cooperative Acute Stroke Study (ECASS) III Trial. Stroke 2012;43(6):1591-5
   PubMed Web of Science ®Google Scholar
• Kleindorfer DO, Broderick JP, Khoury J, et al. Emergency department arrival times after acute ischemic stroke during the 1990s. Neurocrit Care 2007;7(1(31):5
   Google Scholar
• Majersik JJ, Smith MA, Zahuranec DB, et al. Population-based analysis of the impact of expanding the time window for acute stroke treatment. Stroke 2007;38(12):3213-17
   PubMed Web of Science ®Google Scholar
• Bock BF. Proceedings of a National Symposium on Rapid Identification and Treatment of Acute Stroke: response System for Patients Presenting with Acute Stroke. 2012. Available from: www.ninds.nih.gov/news_and_events/proceedings/stroke_proceedings/bock.htm
   Google Scholar
• Fonarow G, Smith E, Saver J, et al. Timeliness of tissue-type plasminogen activator therapy in acute ischemic stroke patient characteristics, hospital factors, and outcomes associated with door-to-needle times within 60 minutes. Circulation 2011;123(7):750-U184
   PubMed Web of Science ®Google Scholar
• Meretoja A, Strbian D, Mustanoja S, et al. Reducing in-hospital delay to 20 minutes in stroke thrombolysis. Neurology 2012;79(4):306-13
   PubMed Web of Science ®Google Scholar
• Weber JE, Ebinger M, Rozanski M, et al. Prehospital thrombolysis in acute stroke: results of the PHANTOM-S pilot study. Neurology 2013;80(2):163-8
   PubMedGoogle Scholar
• Walter S, Kostopoulos P, Haass A, et al. Diagnosis and treatment of patients with stroke in a mobile stroke unit versus in hospital: a randomised controlled trial. Lancet Neurol 2012;11(5):397-404
   PubMed Web of Science ®Google Scholar
• Sarraj A, Grotta JC. Stroke: new horizons in treatment. Lancet Neurol 2014;13(1):2-3
   PubMedGoogle Scholar
• Strbian D, Engelter S, Michel P, et al. Symptomatic intracranial hemorrhage after stroke thrombolysis: the SEDAN score. Ann Neurol 2012;71(5):634-41
   PubMed Web of Science ®Google Scholar
• Urra X, Chamorro A. Emerging issues in acute ischemic stroke. J Neurol 2013;260(6):1687-92
   PubMedGoogle Scholar
• Lou M, Safdar A, Mehdiratta M, et al. The HAT Score: a simple grading scale for predicting hemorrhage after thrombolysis. Neurology 2008;71(18):1417-23
   PubMed Web of Science ®Google Scholar
• Tsivgoulis G, Saqqur M, Barreto A, et al. Validity of HAT score for predicting symptomatic intracranial hemorrhage in acute stroke patients with proximal occlusions: data from randomized trials of sonothrombolysis. Cerebrovasc Dis 2011;31(5):471-6
   PubMedGoogle Scholar
• Rha JH, Shrivastava VP, Wang Y, et al. Thrombolysis for acute ischaemic stroke with alteplase in an Asian population: results of the multicenter, multinational Safe Implementation of Thrombolysis in Stroke-Non-European Union World (SITS-NEW). Int J Stroke 2012. [Epub ahead of print]
   Google Scholar
• Wahlgren N, Ahmed N, Dávalos A, et al. Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study. Lancet 2007;369(9558):275-82
   PubMed Web of Science ®Google Scholar
• Lindsberg PJ, Mattle HP. Therapy of basilar artery occlusion: a systematic analysis comparing intra-arterial and intravenous thrombolysis. Stroke 2006;37(3):922-8
   PubMedGoogle Scholar
• von Kummer R, Hacke W. Safety and efficacy of intravenous tissue plasminogen activator and heparin in acute middle cerebral artery stroke. Stroke 1992;23(5):646-52
   PubMedGoogle Scholar
• del Zoppo GJ, Poeck K, Pessin MS, et al. Recombinant tissue plasminogen activator in acute thrombotic and embolic stroke. Ann Neurol 1992;32(1):78-86
   PubMedGoogle Scholar
• Jansen O, von Kummer R, Forsting M, et al. Thrombolytic therapy in acute occlusion of the intracranial internal carotid artery bifurcation. AJNR Am J Neuroradiol 1995;16(10):1977-86
   PubMedGoogle Scholar
• Lee KY, Han SW, Kim SH, et al. Early recanalization after intravenous administration of recombinant tissue plasminogen activator as assessed by pre- and post-thrombolytic angiography in acute ischemic stroke patients. Stroke 2007;38(1):192-3
   PubMed Web of Science ®Google Scholar
• Rha JH, Saver JL. The impact of recanalization on ischemic stroke outcome: a meta-analysis. Stroke 2007;38(3):967-73
   PubMed Web of Science ®Google Scholar
• Riedel CH, Zimmermann P, Jensen-Kondering U, et al. The importance of size: successful recanalization by intravenous thrombolysis in acute anterior stroke depends on thrombus length. Stroke 2011;42(6):1775-7
   PubMed Web of Science ®Google Scholar
• Kamalian S, Morais LT, Pomerantz SR, et al. Clot length distribution and predictors in anterior circulation stroke: implications for intra-arterial therapy. Stroke 2013;44(12):3553-6
   PubMedGoogle Scholar
• Yoo A, Frei D, Loy D, et al. Abstract T MP34: correlates of clot length assessed by thin-section CT in a consecutive series of stroke patients. Stroke 2014;45(Suppl 1):ATMP34-ATMP
   Google Scholar
• Mokin M, Kass-Hout T, Kass-Hout O, et al. Intravenous thrombolysis and endovascular therapy for acute ischemic stroke with internal carotid artery occlusion: a systematic review of clinical outcomes. Stroke 2012;43(9):2362-8
   PubMed Web of Science ®Google Scholar
• Broderick JP, Meyers PM. Acute stroke therapy at the crossroads. JAMA 2011;306(18):2026-8
   PubMedGoogle Scholar
• Hill MD, Khatri P, Tomsick TA, et al. Letter by Hill et al regarding article, “A cost-utility analysis of mechanical thrombectomy as an adjunct to intravenous tissue-type plasminogen activator for acute large-vessel ischemic stroke”. Stroke 2011;42(12):e641-2
   Google Scholar
• Schott AM. Randomised trials of endovascular treatment of stroke are needed. Lancet Neurol 2010;9(1):30-1
   PubMedGoogle Scholar
• Broderick JP, Palesch YY, Demchuk AM, et al. Endovascular therapy after intravenous t-PA versus t-PA alone for stroke. N Engl J Med 2013;368(10):893-903
   PubMed Web of Science ®Google Scholar
• Ciccone A, Valvassori L; Investigators SE. Endovascular treatment for acute ischemic stroke. N Engl J Med 2013;368(25):2433-4
   PubMed Web of Science ®Google Scholar
• Kidwell CS, Jahan R, Gornbein J, et al. A trial of imaging selection and endovascular treatment for ischemic stroke. N Engl J Med 2013;368(10):914-23
   PubMed Web of Science ®Google Scholar
• Saver JL, Jahan R, Levy EI, et al. Solitaire flow restoration device versus the Merci Retriever in patients with acute ischaemic stroke (SWIFT): a randomised, parallel-group, non-inferiority trial. Lancet 2012;380(9849):1241-9
   PubMed Web of Science ®Google Scholar
• Nogueira RG, Lutsep HL, Gupta R, et al. Trevo versus Merci retrievers for thrombectomy revascularisation of large vessel occlusions in acute ischaemic stroke (TREVO 2): a randomised trial. Lancet 2012;380(9849):1231-40
   PubMed Web of Science ®Google Scholar
• Saqqur M, Uchino K, Demchuk AM, et al. Site of arterial occlusion identified by transcranial Doppler predicts the response to intravenous thrombolysis for stroke. Stroke 2007;38(3):948-54
   PubMed Web of Science ®Google Scholar
• Reddrop C, Moldrich RX, Beart PM, et al. Vampire bat salivary plasminogen activator (desmoteplase) inhibits tissue-type plasminogen activator-induced potentiation of excitotoxic injury. Stroke 2005;36(6):1241-6
   PubMedGoogle Scholar
• Tanswell P, Modi N, Combs D, Danays T. Pharmacokinetics and pharmacodynamics of tenecteplase in fibrinolytic therapy of acute myocardial infarction. Clin Pharmacokinet 2002;41(15):1229-45
   PubMed Web of Science ®Google Scholar
• Hacke W, Albers G, Al-Rawi Y, et al. The Desmoteplase in Acute Ischemic Stroke Trial (DIAS): a phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase. Stroke 2005;36(1):66-73
   PubMed Web of Science ®Google Scholar
• Furlan AJ, Eyding D, Albers GW, et al. Dose escalation of desmoteplase for acute ischemic stroke (DEDAS): evidence of safety and efficacy 3 to 9 hours after stroke onset. Stroke 2006;37(5):1227-31
   PubMed Web of Science ®Google Scholar
• Hacke W, Furlan AJ, Al-Rawi Y, et al. Intravenous desmoteplase in patients with acute ischaemic stroke selected by MRI perfusion-diffusion weighted imaging or perfusion CT (DIAS-2): a prospective, randomised, double-blind, placebo-controlled study. Lancet Neurol 2009;8(2):141-50
   PubMed Web of Science ®Google Scholar
• Parsons MW, Miteff F, Bateman GA, et al. Acute ischemic stroke: imaging-guided tenecteplase treatment in an extended time window. Neurology 2009;72(10):915-21
   PubMed Web of Science ®Google Scholar
• Parsons M, Spratt N, Bivard A, et al. A randomized trial of tenecteplase versus alteplase for acute ischemic stroke. N Engl J Med 2012;366(12):1099-107
   PubMed Web of Science ®Google Scholar
• Haley EC, Thompson JL, Grotta JC, et al. Phase IIB/III trial of tenecteplase in acute ischemic stroke: results of a prematurely terminated randomized clinical trial. Stroke 2010;41(4):707-11
   PubMed Web of Science ®Google Scholar
• Bavarsad Shahripour R, Alexandrov AV. Ancillary approaches to plasminogen activators. Ann N Y Acad Sci 2012;1268:113-19
   PubMedGoogle Scholar
• LaMonte MP, Nash ML, Wang DZ, et al. Argatroban anticoagulation in patients with acute ischemic stroke (ARGIS-1): a randomized, placebo-controlled safety study. Stroke 2004;35(7):1677-82
   PubMedGoogle Scholar
• Sugg RM, Pary JK, Uchino K, et al. Argatroban tPA stroke study: study design and results in the first treated cohort. Arch Neurol 2006;63(8):1057-62
   PubMedGoogle Scholar
• Barreto AD, Alexandrov AV, Lyden P, et al. The argatroban and tissue-type plasminogen activator stroke study: final results of a pilot safety study. Stroke 2012;43(3):770-5
   PubMedGoogle Scholar
• ClinicalTrials.gov. Available from: http://clinicaltrials.gov/ct2/show/NCT01464788
   Google Scholar
• Investigators AESTTA. Emergency administration of abciximab for treatment of patients with acute ischemic stroke: results of a randomized phase 2 trial. Stroke 2005;36(4):880-90
   PubMedGoogle Scholar
• Adams HP, Effron MB, Torner J, et al. Emergency administration of abciximab for treatment of patients with acute ischemic stroke: results of an international phase III trial: abciximab in Emergency Treatment of Stroke Trial (AbESTT-II). Stroke 2008;39(1):87-99
   PubMed Web of Science ®Google Scholar
• Siebler M, Hennerici MG, Schneider D, et al. Safety of Tirofiban in acute Ischemic Stroke: the SaTIS trial. Stroke 2011;42(9):2388-92
   PubMedGoogle Scholar
• Pancioli AM, Broderick J, Brott T, et al. The combined approach to lysis utilizing eptifibatide and rt-PA in acute ischemic stroke: the CLEAR stroke trial. Stroke 2008;39(12):3268-76
   PubMedGoogle Scholar
• Pancioli AM, Adeoye O, Schmit PA, et al. Combined approach to lysis utilizing eptifibatide and recombinant tissue plasminogen activator in acute ischemic stroke-enhanced regimen stroke trial. Stroke 2013;44(9):2381-7
   PubMedGoogle Scholar
• Braaten JV, Goss RA, Francis CW. Ultrasound reversibly disaggregates fibrin fibers. Thromb Haemost 1997;78(3):1063-8
   PubMedGoogle Scholar
• Francis CW, Onundarson PT, Carstensen EL, et al. Enhancement of fibrinolysis in vitro by ultrasound. J Clin Invest 1992;90(5):2063-8
   PubMed Web of Science ®Google Scholar
• Francis CW, Blinc A, Lee S, Cox C. Ultrasound accelerates transport of recombinant tissue plasminogen activator into clots. Ultrasound Med Biol 1995;21(3):419-24
   PubMed Web of Science ®Google Scholar
• Meairs S, Culp W. Microbubbles for thrombolysis of acute ischemic stroke. Cerebrovasc Dis 2009;27(Suppl 2):55-65
   PubMedGoogle Scholar
• Daffertshofer M, Hennerici M. Ultrasound in the treatment of ischaemic stroke. Lancet Neurol 2003;2(5):283-90
   PubMed Web of Science ®Google Scholar
• Polak JF. Ultrasound energy and the dissolution of thrombus. N Engl J Med 2004;351(21):2154-5
   PubMed Web of Science ®Google Scholar
• Alexandrov AV. Ultrasound enhanced thrombolysis for stroke. Int J Stroke 2006;1(1):26-9
   PubMedGoogle Scholar
• Blinc A, Francis CW, Trudnowski JL, Carstensen EL. Characterization of ultrasound-potentiated fibrinolysis in vitro. Blood 1993;81(10):2636-43
   PubMed Web of Science ®Google Scholar
• Blinc A, Kennedy SD, Bryant RG, et al. Flow through clots determines the rate and pattern of fibrinolysis. Thromb Haemost 1994;71(2):230-5
   PubMed Web of Science ®Google Scholar
• Skoloudík D, Fadrná T, Bar M, et al. Changes in haemocoagulation in healthy volunteers after a 1-hour thrombotripsy using a diagnostic 2-4 MHz transcranial probe. J Thromb Thrombolysis 2008;26(2):119-24
   PubMedGoogle Scholar
• Skoloudík D, Fadrná T, Roubec M, et al. Changes in hemocoagulation in acute stroke patients after one-hour sono-thrombolysis using a diagnostic probe. Ultrasound Med Biol 2010;36(7):1052-9
   PubMed Web of Science ®Google Scholar
• Daffertshofer M, Gass A, Ringleb P, et al. Transcranial low-frequency ultrasound-mediated thrombolysis in brain ischemia: increased risk of hemorrhage with combined ultrasound and tissue plasminogen activator: results of a phase II clinical trial. Stroke 2005;36(7):1441-6
   PubMed Web of Science ®Google Scholar
• Alexandrov AV, Molina CA, Grotta JC, et al. Ultrasound-enhanced systemic thrombolysis for acute ischemic stroke. N Engl J Med 2004;351(21):2170-8
   PubMed Web of Science ®Google Scholar
• Tsivgoulis G, Eggers J, Ribo M, et al. Safety and efficacy of ultrasound-enhanced thrombolysis: a comprehensive review and meta-analysis of randomized and nonrandomized studies. Stroke 2010;41(2):280-7
   PubMed Web of Science ®Google Scholar
• Saqqur M, Tsivgoulis G, Nicoli F, et al. The role of sonolysis and sonothrombolysis in acute ischemic stroke: a systematic review and meta-analysis of randomized controlled trials and case-control studies. J Neuroimaging 2014;24(3):209-20
   PubMedGoogle Scholar
• Eggers J, Seidel G, Koch B, König IR. Sonothrombolysis in acute ischemic stroke for patients ineligible for rt-PA. Neurology 2005;64(6):1052-4
   PubMed Web of Science ®Google Scholar
• Eggers J, König IR, Koch B, et al. Sonothrombolysis with transcranial color-coded sonography and recombinant tissue-type plasminogen activator in acute middle cerebral artery main stem occlusion: results from a randomized study. Stroke 2008;39(5):1470-5
   PubMed Web of Science ®Google Scholar
• Gerriets T, Goertler M, Stolz E, et al. Feasibility and validity of transcranial duplex sonography in patients with acute stroke. J Neurol Neurosurg Psychiatry 2002;73(1):17-20
   PubMedGoogle Scholar
• Gerriets T, Postert T, Goertler M, et al. DIAS I: duplex-sonographic assessment of the cerebrovascular status in acute stroke. A useful tool for future stroke trials. Stroke 2000;31(10):2342-5
   PubMedGoogle Scholar
• Kenton AR, Martin PJ, Abbott RJ, Moody AR. Comparison of transcranial color-coded sonography and magnetic resonance angiography in acute stroke. Stroke 1997;28(8):1601-6
   PubMedGoogle Scholar
• Ricci S, Dinia L, Del Sette M, et al. Sonothrombolysis for acute ischaemic stroke. Cochrane Database Syst Rev 2012;10:CD008348
   PubMedGoogle Scholar
• Molina CA, Ribo M, Rubiera M, et al. Microbubble administration accelerates clot lysis during continuous 2-MHz ultrasound monitoring in stroke patients treated with intravenous tissue plasminogen activator. Stroke 2006;37(2):425-9
   PubMed Web of Science ®Google Scholar
• Rubiera M, Ribo M, Delgado-Mederos R, et al. Do bubble characteristics affect recanalization in stroke patients treated with microbubble-enhanced sonothrombolysis? Ultrasound Med Biol 2008;34(10):1573-7
   PubMed Web of Science ®Google Scholar
• Dayton PA, Morgan KE, Klibanov AL, et al. Optical and acoustical observations of the effects of ultrasound on contrast agents. IEEE Trans Ultrason Ferroelectr Freq Control 1999;46(1):220-32
   PubMed Web of Science ®Google Scholar
• Sharma VK, Tsivgoulis G, Lao AY, et al. Quantification of microspheres appearance in brain vessels: implications for residual flow velocity measurements, dose calculations, and potential drug delivery. Stroke 2008;39(5):1476-81
   PubMedGoogle Scholar
• Alexandrov AV. Therapeutic applications of transcranial ultrasound devices. Expert Rev Med Devices 2007;4(1):1-3
   PubMed Web of Science ®Google Scholar
• Lorenzano S, Toni D; Investigators Tt. TESPI (Thrombolysis in Elderly Stroke Patients in Italy): a randomized controlled trial of alteplase (rt-PA) versus standard treatment in acute ischaemic stroke in patients aged more than 80 years where thrombolysis is initiated within three hours after stroke onset. Int J Stroke 2012;7(3):250-7
   PubMedGoogle Scholar
• Ma H, Parsons MW, Christensen S, et al. A multicentre, randomized, double-blinded, placebo-controlled Phase III study to investigate EXtending the time for Thrombolysis in Emergency Neurological Deficits (EXTEND). Int J Stroke 2012;7(1):74-80
   PubMed Web of Science ®Google Scholar